ACS now recommends PSA screening. The pathway after the PSA is our job.
For the first time since 2010, the American Cancer Society makes a direct recommendation to screen. Here is what changed, the evidence behind it, and how it lines up against AUA/SUO and USPSTF.
The author selected the evidence, set the argument and edited the final text. AI tools assisted with drafting and formatting. Every figure was checked against its source.

The ACS guideline published today in CA: A Cancer Journal for Clinicians moves the society from shared decision-making without a screening recommendation to biennial PSA-based screening for average-risk men aged 50 to 69, and annual screening from 45 for Black men and men with a strong family history. The guideline development group concluded there is moderate certainty that benefits outweigh harms.
For urologists, the headline is less about the PSA and more about everything that follows it. The guideline builds harm reduction directly into the recommendation: confirm an elevated PSA before acting, use MRI and/or a validated biomarker before biopsy, and offer active surveillance first for low-risk disease.
| ACS 2010Previous | ACS 2026Released Nov 12, 2026 | AUA/SUO2023, amended 2026 | USPSTF2018, update in progress | |
|---|---|---|---|---|
| Core stance | Informed decision No direct recommendation to screen |
Screen Direct recommendation, after patient understands benefits, limitations and harms |
Shared decision Offer regular screening; PSA as first test |
Grade C Individual decision after discussion with a clinician |
| Average risk | Discussion at 50 | 50 to 69, every 2 years | Baseline PSA may be offered at 45 to 50; every 2 to 4 years at 50 to 69, personalized | 55 to 69; interval not specified |
| Higher risk | Discussion at 45 (Black men, FDR before 65); 40 if several FDRs diagnosed early | Annual from 45 to 69: Black men; FDR before 65; multiple FDRs. Biennial from 45 if one FDR at 65 or older | Offer screening from 40 to 45: Black ancestry, germline mutations, strong family history | Higher risk acknowledged; no separate schedule |
| Older men | Not with life expectancy under 10 years | 70 to 74 individualized; not recommended at 75+ or LE under 10 y. Exception: honoring a very healthy man's request at 75 to 79, especially with a rising PSA, may be reasonable after discussing uncertain benefit and greater harms | Personalize or stop based on age, PSA, risk, life expectancy, health | Grade D Against routine screening at 70+ |
| Elevated PSA | Not specified at this level | Threshold ≥3.0 ng/mL (45 to 69), ≥6.5 (70 to 74). Repeat in 2 wk to 3 mo; if confirmed, offer MRI and/or validated biomarker before biopsy | Repeat PSA before further testing; MRI before biopsy may be used; biomarkers for risk reassessment | Not addressed |
| Low-risk cancer | Not addressed | Offer active surveillance as initial management | Addressed in separate localized PCa guideline | Surveillance noted to reduce overtreatment |
The evidence that moved ACS
ACS built the update on a commissioned systematic review, CISNET modeling of screening strategies, and long follow-up of the randomized trials. The guideline group judged that the evidence now gives moderate certainty that benefits outweigh harms for average-risk men. Certainty is not uniform across the recommendations: starting at 45 for Black men rests on low-certainty evidence, and the annual interval for Black men and the family-history schedules are consensus statements. The key change since 2010 is follow-up length: as the trials matured, the absolute benefit grew and the number of men needed to invite and diagnose fell.
| Trial | Design | Result cited by ACS |
|---|---|---|
| ERSPC, 23-yrPubMed | Men 55 to 69 (core group), PSA every 2 to 4 yr, 7 countries | PCSM RR 0.87 (0.80 to 0.95) ARR 0.22%; NNI 456, NND 12 |
| Göteborg-1, 22-yrPubMed 35422134 | 20,000 men 50 to 64; biennial PSA to age 71 | PCSM RR 0.71 (0.55 to 0.91) |
| CAP, 15-yrPubMed 38581198 | 415,357 men 50 to 69; single PSA invitation, 36% uptake | PCSM RR 0.92 (0.85 to 0.99) ARR 0.09% |
| PLCO, 15-yrPubMed | 76,683 men 55 to 74; six annual PSA tests | No mortality difference; ~90% control-arm PSA testing and low biopsy compliance |
| ERSPC and PLCO reconciliationPubMed 28869989 | CISNET modeling for contamination and lead time | Compatible benefit in both trials vs no screening |
Two details are worth having ready. In ERSPC, the relative reduction attenuated from 9 to 23 years because deaths accrued after screening stopped, yet the absolute reduction tripled (0.07% to 0.22%) and NNI fell from 1,410 to 456. ERSPC also showed roughly a 42% reduction in metastatic disease at 12 years across four centers. CAP shows that even a single invitation to PSA screening can reduce prostate cancer mortality, although the absolute benefit is small. Repeated screening offers more opportunities for early detection, but screening intensity must be balanced against cumulative harms.
The harm-reduction pathway
The 2012 USPSTF D recommendation reflected an unfavorable assessment of screening benefits and harms in an era when reflex biopsy, systematic transrectal sampling and treatment of low-risk cancers were common. The downstream diagnostic and management pathways have since changed substantially, and ACS cites a different evidence base for the pathway it now recommends.
- MRI-guided biopsy selection. ACS notes systematic biopsy alone misses about 37% of GG2+ cancers (Cochrane, PubMed), and that MRI-targeted strategies in screening reduce biopsies and GG1 detection while preserving detection of significant disease (Fazekas, JAMA Oncol 2024; Schoots, Eur Urol 2025). About 9% of GG2+ cancers have a normal MRI, and read quality varies; ACS cites the new PRISM screening MRI standards.
- Biomarkers. 4Kscore, PHI, Stockholm3, IsoPSA, ExoDx and MPS2 generally carry NPV above 90% and can avoid 35% to 40% of biopsies, though performance varies by biomarker, threshold and population. ACS emphasizes high sensitivity for clinically significant cancer and validation in asymptomatic screening populations. ACS draws on ProScreen and the STHLM3-MRI two-year results. No single biomarker is preferred.
- Biopsy route. Transperineal and transrectal targeted biopsy detect significant cancer equally, with a trend toward fewer infections transperineally (Zattoni, Eur Urol Oncol 2024).
- Active surveillance. In Canary PASS (2,155 men, 90% GG1), 10-year metastasis was 1.4% and prostate cancer mortality 0.1%. ProtecT makes the case even more strongly. Its active monitoring arm was far less stringent than modern active surveillance: no protocol MRI or surveillance biopsies, with further evaluation triggered mainly by a rising PSA. It also enrolled much higher-risk men than are typically placed on surveillance in the US, with 23% having Gleason score above 6 and more than one third reclassified as intermediate or high risk. Even so, prostate cancer mortality was low, with about 97% cancer-specific survival at 15 years in every arm.
Also cited: the German PROBASE trial, which is testing a baseline PSA at 45 and found DRE adds little in screening; ACS does not recommend DRE as a screening test.
What this means for urology practices
- Expect volume. A direct ACS recommendation will move primary care. More elevated PSAs will reach us, and the benefit depends on handling them with repeat testing, MRI and biomarkers rather than reflex biopsy.
- MRI capacity and quality are the bottleneck. ACS notes that pre-biopsy MRI remains underused, and least used in lower-income and more socially disadvantaged communities. Programs should audit PI-RADS performance and turnaround before demand rises.
- Consider transperineal biopsy. ACS does not recommend a route, but notes transperineal biopsy can be done without prophylactic antibiotics and may reduce infections and antibiotic resistance, with equivalent detection of significant cancer. Pair it with rigorous surveillance protocols, reserving focal therapy, radiation and surgery for disease that needs treatment.
- Coverage lags. ACA preventive-service mandates follow USPSTF, which remains at Grade C for 55 to 69 while its update proceeds. Follow-up MRI and biomarkers can carry out-of-pocket cost, an access and equity issue in its own right.
- Guidelines now converge on PSA and differ on intensity. ACS favors a fixed biennial schedule starting at 50; AUA/SUO allows 2 to 4 years and an earlier baseline. ACS chose 50 over 45 for average-risk men after modeling the tradeoffs. Both approaches are evidence-informed. Practices should adopt consistent, risk-adapted screening pathways while preserving individualized decisions about screening intensity.
The ACS update is a welcome correction. Screening done well catches the sharks and leaves the minnows alone. The PSA is the entry point; the pathway behind it determines whether we help or harm.
Key references
- Hoffman RM, Wolf AMD, Etzioni RD, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA Cancer J Clin. 2026. doi:10.3322/caac.70112
- Roobol MJ, de Vos II, Månsson M, et al. European Study of Prostate Cancer Screening: 23-year follow-up. N Engl J Med. 2025;393:1669-1680. PubMed
- Frånlund M, et al. Results from 22 years of followup in the Göteborg randomized prostate cancer screening trial. J Urol. 2022;208:292-300. PubMed
- Martin RM, et al. PSA screening and 15-year prostate cancer mortality: secondary analysis of the CAP trial. JAMA. 2024;331:1460-1470. PubMed
- Pinsky PF, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123:592-599. PubMed
- Tsodikov A, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455. PubMed
- Griffin JC, et al. PSA-based screening for prostate cancer: a systematic review to inform an American Cancer Society guideline. Cancer. 2026. PubMed
- Drost FH, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019. PubMed
- Fazekas T, et al. Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2024;10:745-754. PubMed
- Auvinen A, et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial. JAMA. 2024;331:1452-1459. PubMed
- Palsdottir T, et al. Stockholm3-MRI population-based prostate cancer screening study: two-year follow-up. Ann Intern Med. 2026;179:988-995. PubMed
- Newcomb LF, et al. Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer (Canary PASS). JAMA. 2024;331:2084-2093. PubMed
- Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (ProtecT). N Engl J Med. 2023;388:1547-1558. PubMed
- Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, amended 2026). AUA
Disclosures: Dr. Kutikov is a co-founder and co-owner of UrologyWatch.com. He reports consulting/advisory roles with Telix Pharmaceuticals, UroGen Pharma and Insight Medbotics, and equity in Scopia Surgical.
Commentary reflects the author's views. It is written and signed by the author, is separate from the daily ranked edition, and is not medical advice.